This webcast features: Michael Frizberg, President, CMAB – Switzerland and Hong Kong and Eric Langer, Principal, BioPlan Associates
China aspires to become one of if not the leading country contributor to the global pharmaceutical and biopharmaceutical industry by 2030. Large companies in this sector—both international firms expanding their own footprint within China and indigenous Chinese firms establishing both their internal and their global footprints—have witnessed double-digit growth for much of the past five to seven years. The global pharmaceutical and biopharmaceutical industry itself, not just that within China, has entered a period of substantial change. In Part 1 of our series, Michael Frizberg, will highlights key drivers and areas of growth in China biopharma today, as well as cover areas of opportunities for expansion and revenue in today’s markets.
Watch the recorded webcast below.
One thought on “China Biopharma Opportunities”
Thank you for the insights shared on China’s Biopharm.. I registered for and watched on 16Apr20.
Comments are closed.